About this Research Topic
Neuroinflammatory and neurodegenerative disorders affect millions of people worldwide, but the pathophysiological aspects of most of them remain poorly understood.
Neuroinflammation is characterized by increased levels of inflammatory molecules in the Central Nervous system, which could cause progressive neurodegeneration with functional impairment, glial cells involvement and brain damage. Neuroinflammation is essential for recovery from several conditions but may play detrimental roles in neurodegenerative processes. In such disorders, inflammation can be set off by several triggers: protein aggregates, mediators released from injured neurons, accumulation of abnormally modified cellular components, and suppression of mechanisms that would normally control inflammatory processes.
Studies in neurodegenerative diseases, such as Alzheimer’s, Parkinson’s and Huntington’s diseases, Amyotrophic lateral sclerosis, and Vascular dementia have suggested that chronic inflammation is not only the results of neurodegeneration but also plays crucial role in these processes.
Alterations of different signaling pathways in a wide range of nervous system cells have been suggested to be involved in the pathogenesis of neurodegeneration, although they are still far from being completely understood. Due to the limited success of treatments so far, blocking inflammatory signaling pathways involved in neurodegeneration may be a promising strategy for the therapy of neurodegenerative diseases, and many of them have exciting results in animal models and clinical trials.
A wide range of pathologies, such as chronic infections, metabolic diseases, or vascular endothelial dysfunction, among others, play a detrimental role among the most relevant pathophysiological mechanisms in the neurodegeneration process. In this Special Issue, we welcome the submission of original research manuscripts, as well as review articles dissecting various pharmacological targets of inflammation that may serve as a springboard for opening innovative therapeutic avenues focusing on the mechanism role of chronic inflammation at level cellular, tissue and systemic mechanisms in the neurodegenerative processes.
Specifically, articles including the following topics will be expected:
• Neuroinflammation related to chronic infections, metabolic diseases (obesity, diabetes), vascular diseases, ischemic stroke, brain tumors.
• Microbiota and gut-brain-axis involvement in neurodegeneration.
• Inflammaging in neurodegenerative disorders.
• Blood or other biomarkers of neuroinflammation.
• Drug therapies of chronic inflammation in cerebrovascular and neurodegenerative disease.
Neuroinflammation is characterized by increased levels of inflammatory molecules in the Central Nervous system, which could cause progressive neurodegeneration with functional impairment, glial cells involvement and brain damage. Neuroinflammation is essential for recovery from several conditions but may play detrimental roles in neurodegenerative processes. In such disorders, inflammation can be set off by several triggers: protein aggregates, mediators released from injured neurons, accumulation of abnormally modified cellular components, and suppression of mechanisms that would normally control inflammatory processes.
Studies in neurodegenerative diseases, such as Alzheimer’s, Parkinson’s and Huntington’s diseases, Amyotrophic lateral sclerosis, and Vascular dementia have suggested that chronic inflammation is not only the results of neurodegeneration but also plays crucial role in these processes.
Alterations of different signaling pathways in a wide range of nervous system cells have been suggested to be involved in the pathogenesis of neurodegeneration, although they are still far from being completely understood. Due to the limited success of treatments so far, blocking inflammatory signaling pathways involved in neurodegeneration may be a promising strategy for the therapy of neurodegenerative diseases, and many of them have exciting results in animal models and clinical trials.
A wide range of pathologies, such as chronic infections, metabolic diseases, or vascular endothelial dysfunction, among others, play a detrimental role among the most relevant pathophysiological mechanisms in the neurodegeneration process. In this Special Issue, we welcome the submission of original research manuscripts, as well as review articles dissecting various pharmacological targets of inflammation that may serve as a springboard for opening innovative therapeutic avenues focusing on the mechanism role of chronic inflammation at level cellular, tissue and systemic mechanisms in the neurodegenerative processes.
Specifically, articles including the following topics will be expected:
• Neuroinflammation related to chronic infections, metabolic diseases (obesity, diabetes), vascular diseases, ischemic stroke, brain tumors.
• Microbiota and gut-brain-axis involvement in neurodegeneration.
• Inflammaging in neurodegenerative disorders.
• Blood or other biomarkers of neuroinflammation.
• Drug therapies of chronic inflammation in cerebrovascular and neurodegenerative disease.
Keywords: neuroinflammation, neurodegeneration, inflammatory pathways, biomarkers, immune response, inflammaging
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
